Two-component signal transduction as a target for microbial anti-infective therapy.
作者信息
Barrett J F, Hoch J A
机构信息
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA.
出版信息
Antimicrob Agents Chemother. 1998 Jul;42(7):1529-36. doi: 10.1128/AAC.42.7.1529.
Abstract
摘要
相似文献
1
Two-component signal transduction as a target for microbial anti-infective therapy.
Antimicrob Agents Chemother. 1998 Jul;42(7):1529-36. doi: 10.1128/AAC.42.7.1529.
2
Bacterial signaling as an antimicrobial target.
Curr Opin Microbiol. 2020 Oct;57:78-86. doi: 10.1016/j.mib.2020.08.001. Epub 2020 Sep 8.
3
Two-component signal transduction as potential drug targets in pathogenic bacteria.
Curr Opin Microbiol. 2010 Apr;13(2):232-9. doi: 10.1016/j.mib.2010.01.008. Epub 2010 Feb 4.
4
[Interactions between bacteria and antimicrobials during the postantibiotic effect phase].
Rev Esp Quimioter. 1999 Dec;12(4):294-9.
5
Who or what is the source of antibiotic resistance?
J Med Microbiol. 1997 Jun;46(6):461-4.
6
New trends in antimicrobial development.
Curr Med Chem. 1998 Apr;5(2):101-13.
7
Inhibitors targeting two-component signal transduction.
Adv Exp Med Biol. 2008;631:229-36. doi: 10.1007/978-0-387-78885-2_16.
8
Antibiotic resistance in bacteria.
J Med Microbiol. 1992 Jan;36(1):4-29. doi: 10.1099/00222615-36-1-4.
9
Two-component and phosphorelay signal-transduction systems as therapeutic targets.
Curr Opin Pharmacol. 2002 Oct;2(5):507-12. doi: 10.1016/s1471-4892(02)00194-7.
10
Anti-virulence strategies to combat bacteria-mediated disease.
Nat Rev Drug Discov. 2010 Feb;9(2):117-28. doi: 10.1038/nrd3013. Epub 2010 Jan 18.
引用本文的文献
1
Breaking Barriers: Exploiting Envelope Biogenesis and Stress Responses to Develop Novel Antimicrobial Strategies in Gram-Negative Bacteria.
Pathogens. 2024 Oct 11;13(10):889. doi: 10.3390/pathogens13100889.
2
Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape.
Drugs. 2024 Oct;84(10):1167-1178. doi: 10.1007/s40265-024-02084-7. Epub 2024 Sep 6.
3
Combatting Antibiotic-Resistant : Discovery of TST1N-224, a Potent Inhibitor Targeting Response Regulator VraRC, through Pharmacophore-Based Screening and Molecular Characterizations.
J Chem Inf Model. 2024 Aug 12;64(15):6132-6146. doi: 10.1021/acs.jcim.4c01046. Epub 2024 Jul 30.
4
CpxA/R-Controlled Nitroreductase Expression as Target for Combinatorial Therapy against Uropathogens by Promoting Reactive Oxygen Species Generation.
Adv Sci (Weinh). 2023 Sep;10(25):e2300938. doi: 10.1002/advs.202300938. Epub 2023 Jul 5.
5
Targeting multidrug resistant infections with bacterial histidine kinase inhibitors.
Chem Sci. 2023 Apr 11;14(19):5028-5037. doi: 10.1039/d2sc05369a. eCollection 2023 May 17.
6
In Vivo Role of Two-Component Regulatory Systems in Models of Urinary Tract Infections.
Pathogens. 2023 Jan 10;12(1):119. doi: 10.3390/pathogens12010119.
7
Functional Annotation of Hypothetical Proteins From the B13 Strain and Its Association With Pathogenicity.
Bioinform Biol Insights. 2022 Aug 6;16:11779322221115535. doi: 10.1177/11779322221115535. eCollection 2022.
8
Sensing Host Health: Insights from Sensory Protein Signature of the Metagenome.
Appl Environ Microbiol. 2022 Aug 9;88(15):e0059622. doi: 10.1128/aem.00596-22. Epub 2022 Jul 13.
9
The W-Acidic Motif of Histidine Kinase WalK Is Required for Signaling and Transcriptional Regulation in .
Front Microbiol. 2022 Apr 26;13:820089. doi: 10.3389/fmicb.2022.820089. eCollection 2022.
10
Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients.
Front Microbiol. 2022 Apr 19;13:882520. doi: 10.3389/fmicb.2022.882520. eCollection 2022.
本文引用的文献
1
Salmonella entry into mammalian cells: different yet converging signal transduction pathways?
Trends Cell Biol. 1994 Jun;4(6):196-9. doi: 10.1016/0962-8924(94)90136-8.
2
Bacterial two-component signalling as a therapeutic target in drug design. Inhibition of NRII by the diphenolic methanes (bisphenols).
Adv Exp Med Biol. 1998;456:269-86. doi: 10.1007/978-1-4615-4897-3_14.
3
4
Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
MMWR Morb Mortal Wkly Rep. 1997 Sep 5;46(35):813-5.
5
Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus.
Ann Pharmacother. 1997 Sep;31(9):970-3. doi: 10.1177/106002809703100902.
6
Transcriptional regulation of the Enterococcus faecium BM4147 vancomycin resistance gene cluster by the VanS-VanR two-component regulatory system in Escherichia coli K-12.
J Bacteriol. 1997 Sep;179(18):5903-13. doi: 10.1128/jb.179.18.5903-5913.1997.
7
Mutational characterization of promoter regions recognized by the Salmonella dublin virulence plasmid regulatory protein SpvR.
J Bacteriol. 1997 Sep;179(17):5398-406. doi: 10.1128/jb.179.17.5398-5406.1997.
8
Molecular epidemiology and antibiotic susceptibility of enterococci in Cincinnati, Ohio: a prospective citywide survey.
J Clin Microbiol. 1997 Sep;35(9):2342-7. doi: 10.1128/jcm.35.9.2342-2347.1997.
9
High-resolution NMR structure and backbone dynamics of the Bacillus subtilis response regulator, Spo0F: implications for phosphorylation and molecular recognition.
Biochemistry. 1997 Aug 19;36(33):10015-25. doi: 10.1021/bi970816l.
10
Resistance determinants for beta-lactam antibiotics in laboratory mutants of Streptococcus pneumoniae that are involved in genetic competence.
Microb Drug Resist. 1996 Summer;2(2):187-91. doi: 10.1089/mdr.1996.2.187.
Zotero 插件